Answers are grounded in this paper and cite their sources.
Phase 2 trial reduced cytokine levels in chronic myelomonocytic leukemia patients with TET2 mutations, implying ascorbate's therapeutic potential.
The most frequent mutation in CMML is a loss of function missense or frameshift variant in the gene encoding the epigenetic dioxygenase, ten eleven translocation 2 (TET2). Interestingly, deleterious TET2 function on 5-hydroxymethylation can be restored by high dose ascorbate. Macrophages from TET2-deficient mice have been shown to produce increased IL-1β in response to lipopolysaccharide (LPS) challenge (Fuster, et al. 2017, Science; Sano, et al. 2018, J Am Coll Cardiol) but the inflammatory cytokines in TET2 mutant CMML have not been described in detail or the anti-inflammatory responses to ascorbate. Here we report the serial cytokine profiles of bone marrow plasma in a cohort of TET2 mutant CMML patients treated with high dose ascorbate plus azacitidine and show TET2 mutation results in LPS-CD14-NLRP3 inflammasome activation rather than interferon/STING activation in a CRISPR-engineered human model of TET2 mutant monocyte differentiation. Methods: PREACH-M is a phase 2/3 non-randomized, open-label trial in 54 subjects with newly diagnosed CMML in which patients with TET2 mutations are stratified to be treated with high dose sodium ascorbate (30g IV for 7 days then 1.1g oral powder every 28 days) in combination with azacitidine. Vitamin C levels were measured at baseline, cycle 1, 4 and 7. Cytokine profiling was performed at baseline, cycle 4 day 1, cycle 7 day 1, cycle 13 day 1 using Milliplex Human Cytokine/Chemokine Magnetic bead panel. TET2 knockout human cord blood stem progenitor cells versus safe harbor AAVS1 targeting were engineered using dual CRISPR CAS9 sgRNA “hit & run” methods (Nakauchi, et al. 2022, Blood Cancer Discovery) and then differentiated into monocytes/macrophages over 21 days. Results: We analysed the molecular and clinical profiles of TET2 mutant CMML subjects treated with high dose ascorbate. TET2 mutations were detected in 78% overall (n=27) with 76% of these having at least two TET2 variants with variant allele frequency > 3%. Three subjects had TET2 loss of heterozygosity on chromosome 4q24, while one subject had loss of one copy. As of 1st August 2025, 8 patients had completed at least 3 cycles of ascorbate and azacitidine treatment (27 enrolled in the total; 20 subjects in Lenzilumab arm). Vitamin C deficiency (<11 µmol/L) was observed in 29% of subjects in the ascorbate arm and 27% overall; 14% were “at risk” of deficiency (11-23 µmol/L). As expected, treatment with high dose ascorbate significantly increased vitamin C from a mean of 27.9±8.7 at screening to 147.7±52 µmol/L after cycle 1, 80.7±6.5 µmol/L at cycle 3 and 68.2±12.9 µmol/L at cycle 7 (P=0.05, 0.001 and 0.035 respectively). We noted multiple fold change reductions in cytokine levels noted to be produce by innate immune activation including IL-1β (baseline vs cycle 13, P=0.001), IL-8 (baseline vs cycle 7, P=0.04, and baseline vs cycle 13, P=0.001), IL-12p70 (baseline vs cycle 13, P=0.0005), G-CSF (baseline vs cycle 13, P=0.05), GM-CSF (baseline vs cycle 13, P=0.002), IL-1RA (baseline vs cycle 4, P=0.001, baseline vs cycle 7, P=0.03, and baseline vs cycle 13, P=0.007), IL-13 (baseline vs cycle 4, P=0.003, baseline vs cycle 7, P<0.0001, and baseline vs cycle 13, P=0.005), IL-15 (baseline vs cycle 4, P=0.002, baseline vs cycle 7, P=0.07, and baseline vs cycle 13, P<0.0001). Significantly we did not observed changes in IFNγ following ascorbate treatment. Consistent with the plasma results we noted a 2-fold increase in NLRP3 infammasome protein (P=0.0076 and 2.8-fold increase in active IL-1β excretion after LPS/ATP stimulation (P=0.015) in TET2-KO cells compared to safe harbor but no increase in STING activation, tank-binding kinase (P=n.s.) that is associated with interferon signalling.Conclusion: Our preliminary data demonstrates a role for high dose ascorbate in down regulating multiple innate immune cytokines including IL-1β and GM-CSF but not IFNγ in the bone marrow of TET2 mutant CMML patients. This is consistent with our in vitro data showing engineered human TET2-mutated monocytes exhibit hyper-activated innate immune responses through CD14-NLRP3-IL-1β axis reversible with high dose ascorbate. Ascorbate deficiency (< 11 µmol/L) was detected in 27% of CMML patients, a higher rate than reported for the general population (8.7%). In contrast we did not observed hypersensitivity to interferon signalling, tank-binding kinase or STING activation in TET2 mutant monocytes.
No takes yet. Share an insight, caveat, or question.
Ross et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: